What is the primary strategic rationale behind Boston Scientific's acquisition of Preventice Solutions?

The primary rationale is to expand Boston Scientific's portfolio in the rapidly growing cardiac monitoring market, particularly in mobile and remote solutions. Preventice's technology and services are expected to complement BSX's existing offerings and enhance its competitive position.

What are the financial terms of the Preventice acquisition?

The acquisition involves an upfront cash payment of $925 million, with the potential for an additional $300 million in commercial milestone payments. However, considering Boston Scientific's existing 22% equity stake in Preventice, the net cash payment will be approximately $720 million, and the potential milestone payment is reduced to about $230 million.

What types of products and services does Preventice Solutions offer?

Preventice Solutions offers a full range of mobile cardiac health solutions and services. This includes ambulatory cardiac monitors (short and long-term Holter monitors), cardiac event monitors, and mobile cardiac telemetry.

Are there any forward-looking statements in this filing, and what should investors be aware of?

Yes, the filing contains forward-looking statements related to the acquisition, regulatory approvals, product development, and performance. Investors are cautioned that actual results could differ materially from these expectations due to various risks and uncertainties, as detailed in BSX's SEC filings, including its Annual Report on Form 10-K.

BSX 8-K SEC Disclosure — Jan 21, 2021

Summary

Boston Scientific Corporation (BSX) announced on January 21, 2021, that it has entered into a definitive agreement to acquire Preventice Solutions, Inc. This strategic acquisition brings aboard Preventice's comprehensive suite of mobile cardiac health solutions, including various ambulatory cardiac monitors and telemetry services. The deal is structured with an upfront cash payment of $925 million, potentially supplemented by a $300 million commercial milestone payment. Notably, Boston Scientific already held a 22% equity stake in Preventice, which will reduce the net cash outflow and the potential milestone payment. This move signals BSX's intent to strengthen its position in the growing cardiac monitoring market.

Key Highlights

1Boston Scientific (BSX) is acquiring Preventice Solutions, a mobile cardiac health solutions provider.
2The acquisition aims to enhance BSX's offerings in cardiac monitoring technologies.
3The deal includes an upfront cash payment of $925 million.
4An additional $300 million in commercial milestone payments may be paid.
5BSX already owns a 22% stake in Preventice, reducing the net cash outlay.
6The transaction is expected to bolster BSX's presence in the remote cardiac monitoring sector.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Jan 21, 2021)

Summary

Key Highlights

Frequently Asked Questions